Antibodies, Monoclonal
Research News and Information

Sunday, November 22, 2009

Post-transplant EBV-related lymphoproliferative disorder complicating umbilical cord blood transplantation in patients of adrenoleukodystrophy.

13 Dec 2009 EBV-associated post-transplant lymphoproliferative disorder (PTLD) is a well-recognized complication following solid organ transplantation and hematopoietic stem cell transplantation (HSCT) using bone marrow or peripheral blood as stem cell sources, ... Read more...

Superficial granulomatous pyoderma treated preoperatively with infliximab.

13 Dec 2009 We report a case of superficial granulomatous pyoderma (SGP) treated successfully with infliximab. A 71-year-old woman developed erythema, erosions and cribriform scarring in the right periorbital area following enucleation of the right eye. ... Read more...

A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.

29 Nov 2009 BACKGROUND: Despite the increasing cure rates for children with acute lymphoblastic leukemia (ALL), patients who relapse continue to have poor prognosis. The Children's Oncology Group (COG) conducted a limited institution Phase II trial of ... Read more...

Latest indexed articles for 'Antibodies, Monoclonal'

These are the very latest articles for this heading:

• Post-transplant EBV-related lymphoproliferative disorder complicating umbilical cord blood transplantation in patients of adrenoleukodystrophy. 13 Dec 2009
• Superficial granulomatous pyoderma treated preoperatively with infliximab. 13 Dec 2009
• A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. 29 Nov 2009
• Successful treatment with daclizumab of refractory anaplastic lymphoma. 29 Nov 2009
• Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. 13 Nov 2009
• Surface plasmon resonance binding kinetics of Alzheimer's disease amyloid beta peptide-capturing and plaque-binding monoclonal antibodies. Nov 2009
• Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. 30 Oct 2009
• Treatment of sarcoidosis. 30 Oct 2009
• Bevacizumab local complications. 30 Oct 2009
• Angiographic changes after bevacizumab. 30 Oct 2009
• HER2 Intermediate Breast Cancers. 30 Oct 2009
• Lymphatic invasion detected by D2-40/S-100 dual immunohistochemistry does not predict sentinel lymph node status in melanoma. 30 Oct 2009
• Controlling hepatitis C with immunotherapy. 30 Oct 2009
• Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia. 30 Oct 2009
• Assessment of "grading" with Ki-67 and c-kit immunohistochemical expressions may be a helpful tool in management of patients with flat epithelial atypia (FEA) and columnar cell lesions (CCLs) on core breast biopsy. 30 Oct 2009
• Hearing improvement after bevacizumab for neurofibromatosis type 2. 27 Oct 2009
• Hearing improvement after bevacizumab for neurofibromatosis type 2. 27 Oct 2009
• Pregnancy and H1N1 infection. 22 Oct 2009
• A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. 21 Oct 2009
• Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration. 15 Oct 2009

See a longer list of these articles.

Technical information about 'Antibodies, Monoclonal'

Definition: Antibodies produced by clones of cells such as those isolated after hybridization of activated B LYMPHOCYTES with neoplastic cells. These hybrids are often referred to as HYBRIDOMAS.

Registry Number: 0

Descriptor UI: D000911

Alternative terms: Antibodies, Monoclonal; Monoclonal Antibodies;

Related Mesh Headings: Hybridomas;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; biosynthesis; blood; cerebrospinal fluid; classification; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacology; physiology; poisoning; radiation effects; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; pharmacokinetics;

Pharmacological Action: Immunologic Factors;

Tree Number: D12.776.124.486.485.114.224; D12.776.124.790.651.114.224; D12.776.377.715.548.114.224;

History Note: 82

Technical Notes: do not coordinate with ANTIBODY FORMATION for biosyn; ANTIBODY-TOXIN CONJUGATES is available as a toxin carrier: see note there